Suscribirse

DIABETES COMPLICATING PREGNANCY - 02/09/11

Doi : 10.1016/S0889-8545(05)70215-1 
Michael J. Lucas, MD *

Resumen

Obstetricians use a unique form of classification of diabetes in pregnancy originally proposed by Dr. Priscilla White.94 The system was designed to estimate the prognosis for pregnancy outcome for women with diabetes who become pregnant. White first described her classification system in a report entitled, “Pregnancy Complicating Diabetes.” The prognostic system was based on the observation that women in whom diabetes was diagnosed at an earlier age, was of longer duration, or produced vascular complications had a poorer pregnancy prognosis. From an obstetric point of view, diabetes is thought to complicate pregnancy. A large amount of resources is committed to finding, monitoring, and treating diabetes first diagnosed during and presumably induced by pregnancy. White never included an induced form of diabetes in her original classification system; class A diabetes was, in her scheme, subclinical or chemical diabetes that nonetheless preceded pregnancy.

Few pregnant women have had a pregestational diagnosis of diabetes. Validated observations about high rates of fetal morbidity and mortality in women with diabetes induced speculation that unexplained morbidity and mortality might be attributed to undiagnosed diabetes.31 Nonetheless, this latter complication of pregnancy has failed to account for a measurable number of pregnancy losses, and, ironically, the undiagnosed but likely overt diabetic has received little attention until recently in comparison with concern about glucose intolerance and its benign consequences in a much larger number of women.

Another irony in diabetes and pregnancy is the persistent use of glucose tolerance testing in pregnancy. O'Sullivan and Mahan78 evaluated glucose tolerance tests in pregnant women to establish thresholds that were analogous to those used in nonpregnant individuals. Internal medicine specialists subsequently abandoned glucose tolerance testing as inaccurate. Recently, the American Diabetes Association63 has endorsed not only the unique classification system for diabetes in pregnancy that has been used for decades by obstetricians but also the continued use of oral glucose tolerance tests to screen and diagnose diabetes in pregnancy. Despite arguing that universal screening of pregnant women is not supportable because a diagnosis that cannot be predicted on the basis of risk factors is questionable, the association endorsed lower diagnostic thresholds that will increase the prevalence of the diagnosis with little evidence that this change will improve the care and outcome of pregnancies.

Significant changes have occurred over the last 10 years in the diagnosis and treatment of diabetes that impact on pregnancy occurrence in women with diabetes and that affect pregnant women newly diagnosed with diabetes. The Diabetes Care and Complications Trial27 has demonstrated that more strict glycemic normalization reduces the frequency and severity of complications of diabetes and may improve pregnancy outcomes if women are in better glycemic control when they conceive. If the recently reported success of pancreatic islet cell transplants results in widespread availability of this therapeutic modality, the problem of poor periconceptual control may be replaced by a need to consider the impact of new immunosuppressive therapies on the pregnancy.50 Recommendations have changed regarding the diagnosis of diabetes in nonpregnant individuals. The long-standing diagnostic threshold of a fasting glycemic level of 140 mg/dL has been lowered to 126 mg/dL. As a result, the incidence of diabetes will rise, and there is concern that the incidence of diabetes is increasing independently of diagnostic criteria changes owing to an increase in risk factors in the population.39 The primary risk factor of concern is the current “epidemic of obesity.” It is hoped that earlier diagnosis and treatment of diabetes will reduce the incidence and severity of complications of hyperglycemia. Insofar as gestational diabetes is a risk factor for the subsequent development of diabetes in the nonpregnant individual, the importance of the diagnosis in pregnancy would seem to be increased.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Michael J. Lucas, MD, Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, 1501 Kings Highway, P.O. Box 33932, Shreveport, LA 71130–3932, e-mail: [email protected]


© 2001  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 28 - N° 3

P. 513-536 - septembre 2001 Regresar al número
Artículo precedente Artículo precedente
  • CARDIAC DISEASE AND PREGNANCY
  • Alfredo F. Gei, Gary D.V. Hankins
| Artículo siguiente Artículo siguiente
  • ASTHMA IN PREGNANCY
  • Paul J. Wendel

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.